Neumora Therapeutics, a biopharmaceutical firm backed by biotech Amgen and Japan’s SoftBank, on Friday filed for an initial public offering of its shares in New York.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
